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Carbonic anhydrase II as host protein for the creation of a 
biocompatible artificial metathesase 
Jingming Zhao, Anna Kajetanowicz and Thomas R. Ward* 
An artificial metathesase results from incorporation of an Hoveyda–Grubbs catalyst bearing an 
arylsulfonamide anchor within human carbonic anhydrase II. The optimization of the catalytic 
performance is achieved upon combining both chemical and genetic means. Up to 28 TONs were 
obtained within four hours under aerobic physiological conditions.
 
Artificial metalloenzymes result from the incorporation of an 
abiotic cofactor within a host protein.
1
 With biomedical 
applications in mind, it would be desirable to capitalize on a 
host protein which is overexpressed on the surface of cancer 
cells. Accumulation of the abiotic cofactor, which displays high 
affinity for the latter protein, may allow to site-specifically 
uncage a drug.
2
 In this context, the ring-closing metathesis 
(RCM) is an attractive reaction as unactivated diolefins can be 
viewed as bioorthogonal. Furthermore, the intramolecular 
nature of the RCM may facilitate the reaction under highly 
dilute aqueous conditions.
3
 Herein, we report on our efforts to 
exploit human Carbonic Anhydrase II (hCA II hereafter) for the 
creation of a biocompatible artificial metathesase, Scheme 1. 
Certain forms of cancer overexpress hCA IX, a membrane 
bound variant of hCA. These arylsulfonamide binding proteins 
are thus priviledged targets for cancer therapy.
2,4a
 
 
 
 
 
 
 
Scheme 1 Artificial metalloenzyme for ring-closing metathesis. 
Tethering an arylsulfonamide anchor (green) to an Hoveyda-Grubbs 
type catalyst (black) ensures the localization of the metal moiety 
within human Carbonic Anhydrase II (blue).  
 
   Introduction of an arylsulfonamide-anchor on an Hoveyda-
Grubbs 2
nd
 generation-type catalyst ensures its localization 
within carbonic anhydrase.
4
 For this purpose, complexes Boc-
1, Boc-2 and Boc-3,
5
 were deprotected in situ and reacted with 
4-sulfamoylbenzoic acid to afford the corresponding 
sulfonamide-bearing metathesis cofactors 1, 2 and 3, Scheme 
2 (See SI for full experimental details). 
 
Scheme 2  Synthesis of olefin metathesase cofactors 1-3 bearing an 
arylsulfonamide anchor for incorporation within hCA II.  
    
   The catalytic performance of the artificial metathesases was 
evaluated using the ring-closing metathesis of N-tosyl 
diallylamine in the presence of 1 mol % ruthenium. To ensure 
an homogeneous mixture, water/DMSO (9/1) was selected.  
   Comparison of catalysts 1-3 in the absence of hCA II at pH 6.0 
in the presence of 0.1 M MgCl2 reveals that the bulkiest 
catalyst 2 outperforms catalysts 1 and 3 (Table 1, entries 1-3). 
The same trend is observed upon incorporation of the 
cofactors 1-3 into WT hCA II (Table 1, entries 4-6). Catalyst 2 
was thus selected for further optimization. With no MgCl2 
added and at pH 7.0, catalyst 2 and the corresponding 
metathesase 2  WT hCA II afforded 23 and 14 turnovers after 
four hours at 37 °C. Performing catalysis under strict exclusion 
of oxygen yielded very similar results.  
   Reactions carried out at pH 7.0 and in the presence of 154 
mM NaCl (corresponding to physiological conditions) yielded 
32 and 21 TONs for 2 and 2  WT hCA II respectively (Table 1, 
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entries 15, 16). As can be appreciated, the TON of the catalyst 
is pH dependent, both in the presence and in the absence of 
hCA II. The best performance is obtained at lower pH and high 
salt concentration (Table 1, entries 12, 13). As for other 
artificial metalloenzymes, we do not believe that the pI of the 
host protein influences significantly the catalyst performance.
6
 
Compared to the other four artificial metathesases reported to 
date,
3a-3e
 the system presented herein presents the following 
advantageous features (Table 2): i) it does not require an inert 
atmosphere; ii) the substrate concentration is the lowest of all 
systems reported to date; iii) except for the metathesase 
based on FhuA (which requires SDS, a surfactant), it displays 
the highest turnover frequency and iv) it catalyses RCM at pH 
7.0, temperature 37 °C and physiological [NaCl] 
concentrations. These results thus suggest that WT hCA II is a 
suitable host for the creaction of artificial metathesases 
operating under physiological conditions and at low catalyst 
concentrations (i.e. 10 µM). 
 
Table 1  Selected results for the ring-closing metathesis of N-tosyl 
diallylamine.a 
 
 
    
 
 
   To gain insight into the localization of rac-2 within WT hCA II, 
both enantiomers were docked using the GOLD program,
7
 
Figure 1. As can be appreciated, the cofactor fits nicely within 
the cone-shaped binding funnel of hCA II, presenting its 
alkylidene moiety at the surface of the protein (Figure 1). With 
the aim of improving the TON of the artificial metathesase, 
residues I91, F131, L198, K170 were subjected to site-directed 
mutagenesis (Table 1, entries 20-27). Lypophylic, polar and 
potentially coordinating aminoacid residues were engineered 
into these positions. A selection of mutants tested is presented 
in Table 1, entries 20-27. To our delight, 2  hCA II L198H 
yielded significantly improved catalytic performance: up to 28 
TONs under physiological conditions (Table 1, entry 24). 
Considering that both His198 and Phe198 affort similar TONs, 
we do not believe that the former residue coordinates to 
ruthenium. At this point however,  it is difficult to rationalize 
or predict the effect a point mutations on the outcome of 
catalysis. 
 
 
 
 
 
 
 
 
 
 
                        (a)                                                  (b) 
Fig. 1 Docked structure of (R)-2  WT hCA II (a) and (S)-2  WT hCA II (b). 
The ruthenium cofactor is displayed as stick and hCA II as solvent accessible 
transparent surface. Residues subjected to mutagenesis are highlighted in 
magenta. 
   In order to ensure localisation of the cofactor 2 within hCA II 
under catalytic conditions, its affinity was determined using 
the dansylamide displacement assay.
8
 Dansylamide (DNSA) 
displays enhanced fluorescence upon incorporation within hCA 
II. The non-covalent probe can be displaced by high affinity 
arylsulfonamide-bearing hCA II inhibitors, leading to a 
decrease in fluorescence.  
   For DNSA, we obtained a Kd = 4.83 µM and 17.35 µM for WT 
hCA II and L198H hCA II respectively. The displacement assay 
(See SI for details) yielded Kd = 90.40 nM and 205.10 nM for 2 
 WT hCA II and 2  hCA II L198H respectively, Figure 2. 
Although we cannot exclude additional non-specific binding on 
the surface of hCA II, we feel that the exquisite specificity of 
arylsulfonamides most probably ensures selective binding to 
the Zn(His)3 moiety. We tentatively attribute the modest 
quality of the fit to the use of a rac-2 (and thus the presence of 
two inhibitors with potentially different affinities). Under 
catalytic conditions 96 % and 93 % of 2 is bound to WT hCA II 
and hCA II L198H respectively. 
 
  
 
Entry Catalyst hCA II pH [MClx] mol/l TON
b 
1 1  6.0 MgCl2 0.1 20 ± 0.4 
2 2  6.0 MgCl2 0.1 48 ± 0.8 
3 3  6.0 MgCl2 0.1 25 ± 0.7 
4 1 WT 6.0 MgCl2 0.1 13 ± 1.3 
5 2 WT 6.0 MgCl2 0.1 45 ± 2.0 
6 3 WT 6.0 MgCl2 0.1 16 ± 1.0 
7 2 WT 6.0 NaCl 0.2 40 ± 1.5 
8 2 WT 7.0 NaCl 0.2 28 ± 1.1 
9 2  7.0  23 ± 2.1 
10 2 WT 7.0  14 ± 0.5 
11c 2 WT 7.0  20 ± 2.3 
12 2  5.0 MgCl2 0.5 85 ± 1.0 
13 2 WT 5.0 MgCl2 0.5 78 ± 2.5 
14 2 WT 6.0  23 ± 2.6 
15 2 WT 8.0  21 ± 1.2 
16 2  7.0 NaCl 0.154 32 ± 2.0 
17 2 WT 7.0 NaCl 0.154 21 ± 1.8 
18 2 WT 7.0 NaCl 0.5 32 ± 1.8 
19 2 WT 7.0 NaCl 1.0 29 ± 1.2 
20 2 I91A 7.0  18 ± 3.3 
21 2 F131A 7.0  16 ± 1.3 
22 2 L198F 7.0  18 ± 1.6 
23 2 L198H 7.0  22 ± 0.1 
24 2 L198H 7.0 NaCl 0.154 28 ± 0.6 
25 2 L198A 7.0  15 ± 1.7 
26 2 L198Q 7.0  14 ± 0.1 
27 2 K170A 7.0  15 ± 2.0 
a Reaction conditions: [substrate] 1 mM, [catalyst] 10 µM, [hCA II] 12 µM, 
Vtot 200 µL (VDMSO 20 µL), 37 °C for 4 hours. The reactions were carried out 
in triplicate. Very similar results were obtained under rigorous exclusion of 
oxygen. b Turnover number. c [substrate] 5 mM, [catalyst] 50 µM, [hCA II] 
60 µM.  
Zn 
I91 
F131 
L198 
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Table 2  Summary of the catalytic performance of artificial metathesases reported to date  
 
 
 
 
Fig. 2 Determination of the dissociation constant of 2  hCA II using the 
dansylamide displacement assay: WT hCA II (a) and L198H hCA II (b) [hCA 
II]=0.25 µM,  [Dansylamide] = 20 µM, See SI for full experimental details. All 
measurements were performed in duplicate. 
Conclusions 
In summary, we have developed an artificial metathesase 
relying on hCA II as host protein. Importantly, the present 
system operates under aerobic physiological conditions and at 
low catalyst concentrations (i.e. 10 µM). Current efforts are 
directed at evaluating hCA IX, a cell-surface hCA variant which 
is overexpressed in various forms of cancer. 
 
 
 
 
 
 
 
 
 
Experimental section 
Typical procedure for the ring closing metathesis 
The following stock solutions were prepared: catalyst 2 (200 
µM) in DMSO, N-tosyldiallylamine (20 mM) in DMSO and hCA II 
isoform solution (13.3 µM) in phosphate buffer (0.1 M, pH 
7.0). 
   To a small glass vial, the catalyst 2 stock solution (10 µL) was 
added to the protein stock solution (180 µL). The mixture was 
incubated at 37 °C for 20 min. The N-tosyldiallylamine stock 
solution (10 µL) was added and the reaction vial was placed in 
the incubator (37 °C) for 4 h at 200 rpm. 
   After completion of the reaction, 2-phenylethanol (100 µL,  
used as internal standard, 1 mM in H2O) and MeOH (700 µL) 
were added. The mixture was transferred to an eppendorf 
tube and centrifuged at 14’000 rpm for 15 minutes to 
precipitate hCA II. The supernatant (500 µL) was transferred in 
an HPLC vial and water (500 µL) was added. The sample was 
then subjected to reversed phase HPLC for TON analysis. 
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[substrate]  
5 mM 
 
15.21 mM  
100 mM 
 
8 mM 
 
1 mM 
Reaction 
type 
RCM RCM ROMP RCM RCM 
Anchoring of 
Ru-cofactor 
covalent supramolecular covalent covalent dative 
Host protein 
MjHSP[1] 
4 mol% 
Avidin 
4.8 mol% 
FhuA DCVFtev[2] 
0.08 mol% 
α-Chymotrypsin 
0.63 mol% 
hCA II 
1 mol% 
Temp. Time 
pH 
45 °C 
12 h 
2 
40 °C 
16 h 
4 
25 °C 
68 h 
7 
25 °C 
2 h 
7  
37 °C 
4 h 
7 
Reaction 
conditions 
10 mM HCl,  
Water/t-BuOH 
4/1 
under air 
0.1 M acetate 
Water/DMSO 
5/1 
 0.5 M MgCl2, 
under air 
Water/THF 
9/1 
 SDS 1%  
under N2 
Degassed 
100 mM KCl, 
 under N2 
0.1 M phosphate 
Water/DMSO 
9/1  
under air 
TON 25 20 955 20 28 
[1] MjHSP: M. jannaschii small heat shock protein.  
[2]  GH-FhuA DCVFtev: engineered variants of the β-barrel ferric hydroxamate uptake protein component A 
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